Cargando…
Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients
Lung cancer continues to be a major worldwide health issue, with more than 50% of patients having incurable metastatic disease at diagnosis. Fortunately, the advanced lung cancer treatment landscape is changing rapidly as a result of the positive impact of effective inhibitors of tumor driver mutati...
Autores principales: | Bonomi, Philip, Fidler, Mary Jo, Shah, Palmi, Borgia, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893632/ https://www.ncbi.nlm.nih.gov/pubmed/31652685 http://dx.doi.org/10.3390/cancers11111619 |
Ejemplares similares
-
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
por: Yun, Nicole K., et al.
Publicado: (2021) -
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?
por: McGovern, Josh, et al.
Publicado: (2022) -
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
por: Fidler, Mary Jo, et al.
Publicado: (2018) -
Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy
por: Fidler, Mary Jo, et al.
Publicado: (2017) -
Cancer Cachexia and Dysregulated Phosphate Metabolism: Insights from Mutant p53 and Mutant Klotho Mouse Models
por: Brown, Ronald B.
Publicado: (2022)